key: cord-0878020-vs7gipnx authors: Jacobs, Jana L; Mellors, John W title: Detection of SARS-CoV-2 RNA in Blood of Patients with COVID-19: What Does It Mean? date: 2020-09-08 journal: Clin Infect Dis DOI: 10.1093/cid/ciaa1316 sha: d37b5eef868204c8f7dd1b7c21d2ef865e4bf1d6 doc_id: 878020 cord_uid: vs7gipnx nan A c c e p t e d M a n u s c r i p t The SARS-CoV-2/COVID-19 pandemic has severely impacted global societies and taken hundreds of thousands of lives prematurely. A striking paradox about SARS-CoV-2 infection is the broad range of clinical manifestationsranging from asymptomatic infection, to more severe disease requiring hospitalization, to death despite intensive care. Such a broad range of illness is characteristic of other infectious diseases including poliovirus infection for which only 1 in 100 to 1 in 1000 infections result in paralytic disease with the remainder being asymptomatic or minimally symptomatic [1] . Initial studies of prognosis in SARS-CoV-2/COVID-19 have focused on host risk factors for severe disease, which have identified older age, male sex, non-white race, and comorbidities including obesity, among others [2] . Most studies of SARS-CoV-2 pathogenesis have focused on cellular and serologic responses, immunopathology, and qualitative or semi-quantitative measurements of SARS-CoV-2 RNA in the nasopharynx. The contribution of immunopathology to COVID-19 disease severity has been established. Host response to infection is generally a well-regulated process containing complex checks and balances to avoid host injury from overactive innate or adaptive immune responses. In COVID-19, however, there can be immune dysregulation and excessive inflammatory responses that can tip the balance toward severe disease [3, 4] . As for most virus infections, some combination of virus-and immune-mediated damage is likely responsible for severe disease. Analyses of SARS-CoV-2 RNA in the nasopharynx, often inappropriately termed "viral load", have not shown consistent associations with asymptomatic versus symptomatic disease or with severity of symptomatic disease [5] . This result is not surprising given that measuring viral RNA at the local site of initial infection may not provide an accurate assessment of viral replication in the lower respiratory track or dissemination of virus through blood to other organs. For many infections, including HIV and Ebola as examples, the quantity of the pathogen in blood is a strong indicator of prognosis [6, 7] . ddPCR is a natural choice for detection of a novel pathogen early in the course of an outbreak since materials required for constructing a viral RNA standard curve are not yet widely available. Nevertheless, it is important to note that the sensitivity of any PCR assay is dependent upon a variety of factors, many of which are not intrinsic to the PCR technology used, such as the integrity and amount of source material assayed, the efficiency of recovery A c c e p t e d M a n u s c r i p t of nucleic acid from the sample, and the proportion of total sample assayed, along with added effects of primer and probe design on PCR efficiency and product detection. Indeed, many highly sensitive assays based on traditional quantitative PCR have been reported in the literature, including a RT-qPCR assay with single copy sensitivity for detection of HIV-1 RNA in plasma [10] . It is likely that application of such single copy assays to blood samples from patients with COVID-19 will increase the frequency of SARS-CoV-2 RNA detection in severe disease and possibly less severe disease. Social serology; antibody levels in a normal young population during an epidemic of poliomyelitis Predictors of Adverse Prognosis in Covid-19: A Systematic Review and Meta-analysis Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea Clinical characteristics of 154 patients suspected of having Ebola virus disease in the Ebola holding center of Jui Government Hospital in Sierra Leone during the 2014 Ebola outbreak Prognosis in HIV-1 infection predicted by the quantity of virus in plasma Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity A Simpler and More Sensitive Single-Copy HIV-1 RNA Assay for Quantification of Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team A c c e p t e d M a n u s c r i p t